ArticleScientific reports2026
Molecular docking and dynamics reveal novel CDK6 inhibitors for targeted glioblastoma therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bivalent multi-epitope vaccine targeting CSP and TRAP of Plasmodium vivax designed through immunoinformatics and structural bioinformatics.BMC microbiology · 2026Article
- Integrated experimental and computational evaluation of Anagallis foemina derived terpenoids against carbapenem resistant Acinetobacter baumannii.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiform (GBM) is the most deadly type of primary CNS tumor and is linked to dysregulation of the CDK4/6 pathway, poor prognosis, and high rate of post-surgical recurrence. One practical strategy for overcoming treatment resistance in GBM is targeting CDK6. The main goal of this study was to identify new primary amine-containing compounds with specific inhibitory potential against CDK6 using in silico tools. A thorough in silico pipeline comprising ligand-based virtual screening (LBVS), molecular docking, ADMET, density functional theory (DFT) analysis, and molecular dynamics (MD) simulation was used in this investigation. First, molecular docking against CDK6 was performed on 109 bioactive compounds that had been screened using ligand-based virtual screening (LBVS). According to the docking analysis, 48 compounds exhibited more favorable Glide docking scores than the reference compound CCL (− 11.174 kcal·mol⁻¹), among which compound 21 showed the most favorable score (− 12.811 kcal·mol⁻¹). Additionally, the interaction study demonstrated that the target selectivity of compound 21 was improved by preferential interactions to the polar residues Lys43 and His100. Compound 21 satisfied Lipinski’s rule of five (LRo5) and exhibited a favorable predicted toxicity profile, along with predicted blood–brain barrier (BBB) permeability, based on analysis using the SwissADME online tool. Through the demonstration of the stability, moderate reactivity, and minimal off-target potential of compound 21, Density Functional Theory (DFT) studies provided additional validation for its electrical characteristics. Further molecular dynamics simulation straddling 250ns confirmed the stability and flexibility of compound 21. These findings demonstrated compound 21 as a predicted lead and it could serve as a potential therapeutic agent targeting CDK6 in GBM treatment. However, in vitro and in vivo studies are required for the further clinical application of compound 21.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.